BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 8337824)

  • 1. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
    Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
    Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to human and non-human primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus.
    Bergmeier LA; Walker J; Tao L; Cranage M; Lehner T
    Immunology; 1994 Oct; 83(2):213-20. PubMed ID: 7835937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-mediated immune response of macaques immunized with low doses of simian immunodeficiency virus (SIV).
    Dittmer U; Spring M; Petry H; Nisslein T; Rieckmann P; Lüke W; Stahl-Hennig C; Hunsmann G; Bodemer W
    J Biotechnol; 1996 Jan; 44(1-3):105-10. PubMed ID: 8717393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-dependent enhancement and neutralization pattern of sera from SIV-infected or HIV-2-vaccinated rhesus monkeys.
    Le Grand R; Vogt G; Chapel A; Dormont D
    J Med Primatol; 1991 Jun; 20(4):172-6. PubMed ID: 1942007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
    Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
    J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.
    Rasmussen RA; Montefiori DC; Robinson HL; McClure HM; Ruprecht RM
    J Infect Dis; 2001 Dec; 184(12):1603-7. PubMed ID: 11740737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells.
    Putkonen P; Nilsson C; Hild K; Benthin R; Cranage M; Aubertin AM; Biberfeld G
    J Med Primatol; 1993; 22(2-3):100-3. PubMed ID: 8411101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies.
    Jaspan HB; Robinson JE; Amedee AM; Van Dyke RB; Garry RF
    J Clin Virol; 2004 Nov; 31(3):190-7. PubMed ID: 15465411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Spear GT; Takefman DM; Sharpe S; Ghassemi M; Zolla-Pazner S
    Virology; 1994 Nov; 204(2):609-15. PubMed ID: 7941328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.